Current status of selective nonsteroidal anti-inflammatory drug-COX-2 inhibitor use in outpatients with low back pain and cardiovascular comorbidities: An Analysis of the NAMCS Database.
{"title":"Current status of selective nonsteroidal anti-inflammatory drug-COX-2 inhibitor use in outpatients with low back pain and cardiovascular comorbidities: An Analysis of the NAMCS Database.","authors":"Yujian Liu, Jian Lu, Guangwu Liu","doi":"10.47391/JPMA.20611","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To analyse prescribing patterns of cyclooxygenase-2 inhibitor for low-back pain patients with cardiovascular comorbidities in American outpatient settings.</p><p><strong>Methods: </strong>The data of this retrospective, cross-sectional study were from the 2007-2019 National Ambulatory Medical Care Survey except 2017 for which data were not available. Data related to low-back pain patients of either gender aged ≥20 years. Those having cardiovascular comorbidities were placed in group A, while those without such comorbidities were placed in group B. Descriptive statistics were employed to evaluate visit characteristics, stratified by cyclooxygenase-2 inhibitor use. Multivariable logistic regression analysis was utilised to assess factors associated with cyclooxygenase-2 inhibitor prescriptions. Data was analysed using R 4.1.2.</p><p><strong>Results: </strong>Of the 242.65 million patients with 107.19(44.2%) females, 76.83 million (31.7%) were in group A and 165.82 million (68.3%) in group B. Compared to group B patients, those in group A were older (62.0±14.1years vs 49.7±16.1 years, p<0.01) and had a higher prevalence of cyclooxygenase-2 inhibitor use (p=0.01). Overall, 5.2 million (2.14%) patients were prescribed cyclooxygenase-2 inhibitors. Those using cyclooxygenase-2 inhibitor exhibited a higher prevalence of cardiovascular comorbidities (p=0.01), especially hypertension (p=0.01), and were older in age (p<0.01). Older age (odds ratio = 1.019, 95% confidence interval: 1.003-1.035; p<0.05) and higher prevalence of cardiovascular comorbidities (odds ratio = 1.638, 95% CI: 1.017-2.637; p<0.05) were associated with increased likelihood of receiving cyclooxygenase-2 inhibitor prescriptions.</p><p><strong>Conclusions: </strong>Cyclooxygenase-2 inhibitor use was positively correlated with age and cardiovascular comorbidities among low-back pain patients in American ambulatory care, suggesting potential contradiction to current medication guidelines and heightened risk of adverse cardiovascular events.</p>","PeriodicalId":54369,"journal":{"name":"Journal of the Pakistan Medical Association","volume":"75 8","pages":"1218-1223"},"PeriodicalIF":0.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Pakistan Medical Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.47391/JPMA.20611","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To analyse prescribing patterns of cyclooxygenase-2 inhibitor for low-back pain patients with cardiovascular comorbidities in American outpatient settings.
Methods: The data of this retrospective, cross-sectional study were from the 2007-2019 National Ambulatory Medical Care Survey except 2017 for which data were not available. Data related to low-back pain patients of either gender aged ≥20 years. Those having cardiovascular comorbidities were placed in group A, while those without such comorbidities were placed in group B. Descriptive statistics were employed to evaluate visit characteristics, stratified by cyclooxygenase-2 inhibitor use. Multivariable logistic regression analysis was utilised to assess factors associated with cyclooxygenase-2 inhibitor prescriptions. Data was analysed using R 4.1.2.
Results: Of the 242.65 million patients with 107.19(44.2%) females, 76.83 million (31.7%) were in group A and 165.82 million (68.3%) in group B. Compared to group B patients, those in group A were older (62.0±14.1years vs 49.7±16.1 years, p<0.01) and had a higher prevalence of cyclooxygenase-2 inhibitor use (p=0.01). Overall, 5.2 million (2.14%) patients were prescribed cyclooxygenase-2 inhibitors. Those using cyclooxygenase-2 inhibitor exhibited a higher prevalence of cardiovascular comorbidities (p=0.01), especially hypertension (p=0.01), and were older in age (p<0.01). Older age (odds ratio = 1.019, 95% confidence interval: 1.003-1.035; p<0.05) and higher prevalence of cardiovascular comorbidities (odds ratio = 1.638, 95% CI: 1.017-2.637; p<0.05) were associated with increased likelihood of receiving cyclooxygenase-2 inhibitor prescriptions.
Conclusions: Cyclooxygenase-2 inhibitor use was positively correlated with age and cardiovascular comorbidities among low-back pain patients in American ambulatory care, suggesting potential contradiction to current medication guidelines and heightened risk of adverse cardiovascular events.
期刊介绍：
Primarily being a medical journal, JPMA publishes scholarly research focusing on the various fields in the areas of health and medical education. It publishes original research describing recent advances in health particularly clinical studies, clinical trials, assessments of pathogens of diagnostic importance, medical genetics and epidemiological studies. Review articles highlighting importance of various issues in the domain of public health, drug research and medical education are also accepted. As a leading journal of South Asia, JPMA remains cognizant of the recent advances in the rapidly growing fields of biomedical sciences, it invites and encourages scholars to write short reviews and invited editorials on the emerging issues. We particularly aim to promote health standards of developing countries by encouraging manuscript submissions on issues affecting the public health and health delivery services.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
